NCT00738088

Variation in Sulphonylurea Response in Type 2 Diabetes

The Use of Glycaemic Response to Sulphonylureas as a Tool to Investigate Type 2 Diabetes Pathophysiology

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: NHS Tayside · Other Government
• Sex: All
• Age: 35 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study hypothesis is that people who respond well to sulphonylureas have a different underlying cause for their diabetes than people who respond poorly to this medication. We are using two approaches to study this. In one approach we look at people who have previously responded well or poorly, confirm this by rechallenging them with a sulphonylurea drug, and then looking at how well they produce insulin in response to glucose and an intravenous sulphonylurea called tolbutamide. The second approach identifies people with a certain genetic predisposition to diabetes (due to changes in the TCF7L2 gene) and then looks at how well they respond to sulphonylurea medication.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	gliclazide	Gliclazide 80mg bd for 6 weeks

Timeline

• Start date: 2007-06-01
• Primary completion: 2011-03-03
• Completion: 2011-03-03
• First posted: 2008-08-20
• Last updated: 2018-05-03

Locations

1 site across 1 country: United Kingdom